

Michele M Castro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4035374/michele-m-castro-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

1,552
citations

23
h-index

39
g-index

52
ext. papers

1,698
ext. citations

4.5
avg, IF

4.4
L-index

#	Paper	IF	Citations
50	Low load strength training, associated with or without blood flow restriction increased NO production and decreased production of reactive oxygen species in the in rats aorta.. <i>Life Sciences</i> , 2022 , 120350	6.8	1
49	Omeprazole induces vascular remodeling by mechanisms involving xanthine oxidoreductase and matrix metalloproteinase activation. <i>Biochemical Pharmacology</i> , 2021 , 190, 114633	6	1
48	MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin. <i>Biochemical Pharmacology</i> , 2021 , 193, 114744	6	4
47	Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. <i>Life Sciences</i> , 2020 , 244, 117153	6.8	4
46	Study of the Biomechanical and Histological Properties of the Abdominal Aorta of Diabetic Rats Exposed to Cigarette Smoke. <i>Journal of Vascular Research</i> , 2019 , 56, 255-266	1.9	4
45	Nitrite treatment downregulates vascular MMP-2 activity and inhibits vascular remodeling in hypertension independently of its antihypertensive effects. <i>Free Radical Biology and Medicine</i> , 2019 , 130, 234-243	7.8	18
44	Matrix metalloproteinase (MMP)-2 activation by oxidative stress decreases aortic calponin-1 levels during hypertrophic remodeling in early hypertension. <i>Vascular Pharmacology</i> , 2019 , 116, 36-44	5.9	13
43	Ethanol withdrawal increases blood pressure and vascular oxidative stress: a role for angiotensin type 1 receptors. <i>Journal of the American Society of Hypertension</i> , 2018 , 12, 561-573		4
42	Quercetin decreases the activity of matrix metalloproteinase-2 and ameliorates vascular remodeling in renovascular hypertension. <i>Atherosclerosis</i> , 2018 , 270, 146-153	3.1	31
41	Nitrite exerts antioxidant effects, inhibits the mTOR pathway and reverses hypertension-induced cardiac hypertrophy. <i>Free Radical Biology and Medicine</i> , 2018 , 120, 25-32	7.8	18
40	Long-Term Excessive Selenium Supplementation Induces Hypertension in Rats. <i>Biological Trace Element Research</i> , 2018 , 182, 70-77	4.5	9
39	Reply to: "Quercetin affects gelatinases in rat aortas: Some comments". <i>Atherosclerosis</i> , 2018 , 275, 446-447		9
38	Lack of scarring is not always a sign of cardiac health: Functional and molecular characterization of the rat heart following chronic reperfusion. <i>PLoS ONE</i> , 2018 , 13, e0209190	3.7	
37	The potential of stimulating nitric oxide formation in the treatment of hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 543-556	6.4	23
36	Matrix Metalloproteinase-2 Activity is Associated with Divergent Regulation of Calponin-1 in Conductance and Resistance Arteries in Hypertension-induced Early Vascular Dysfunction and Remodelling. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017 , 121, 246-256	3.1	7
35	[PP.22.25] SODIUM OVERLOAD AFFECTS THE SYMPATHOVAGAL BALANCE AND INDUCES MORPHOLOGICAL AND FUNCTIONAL CHANGES IN RAT AORTA. <i>Journal of Hypertension</i> , 2017 , 35, e283	1.9	
34	Metabolic parameters and responsiveness of isolated iliac artery in LDLr mice: role of aerobic exercise training. <i>American Journal of Cardiovascular Disease</i> , 2017 , 7, 64-71	0.9	1

33	Matrix metalloproteinase (MMP)-2 decreases calponin-1 levels and contributes to arterial remodeling in early hypertension. <i>Biochemical Pharmacology</i> , 2016 , 118, 50-58	6	19
32	Reduced levels of potential circulating biomarkers of cardiovascular diseases in apparently healthy vegetarian men. <i>Clinica Chimica Acta</i> , 2016 , 461, 110-3	6.2	10
31	Matrix Metalloproteinase 2 as a Potential Mediator of Vascular Smooth Muscle Cell Migration and Chronic Vascular Remodeling in Hypertension. <i>Journal of Vascular Research</i> , 2015 , 52, 221-31	1.9	84
30	Smoothelin-B is not a target of matrix metalloproteinase (MMP)-2 in the vasculature of endotoxemic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2014 , 92, 887-91	2.4	1
29	Remodeling of aorta extracellular matrix as a result of transient high oxygen exposure in newborn rats: implication for arterial rigidity and hypertension risk. <i>PLoS ONE</i> , 2014 , 9, e92287	3.7	18
28	Matrix Metalloproteinases and Hypertension 2014 , 279-293		1
27	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. <i>Biochemical Pharmacology</i> , 2013 , 86, 469-75	6	9
26	Tempol inhibits TGF- β and MMPs upregulation and prevents cardiac hypertensive changes. <i>International Journal of Cardiology</i> , 2013 , 165, 165-73	3.2	39
25	Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling. <i>International Journal of Cardiology</i> , 2013 , 167, 1199-205	3.2	31
24	Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations. <i>Current Drug Targets</i> , 2013 , 14, 335-343	3	2
23	Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass. <i>Critical Care Medicine</i> , 2013 , 41, 2512-20	1.4	22
22	Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. <i>Current Drug Targets</i> , 2013 , 14, 335-43	3	45
21	Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. <i>Nitric Oxide - Biology and Chemistry</i> , 2012 , 26, 162-8	5	51
20	Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 662-8	9.4	35
19	Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase (MMP)-2. <i>FASEB Journal</i> , 2012 , 26, lb657	0.9	
18	Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. <i>Pharmacological Research</i> , 2011 , 64, 567-72	10.2	67
17	Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. <i>Pharmacological Research</i> , 2011 , 64, 551-60	10.2	66
16	Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. <i>Critical Care Medicine</i> , 2011 , 39, 349-56	1.4	41

15	Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011 , 108, 318-25	3.1	42
14	Smoothelin-B: a potential target of matrix metalloproteinase (MMP)-2 in the vasculature of endotoxemic rats. <i>FASEB Journal</i> , 2011 , 25, 1115.19	0.9	
13	Spirolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. <i>British Journal of Pharmacology</i> , 2010 , 160, 77-87	8.6	75
12	Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H45-51	5.2	51
11	Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. <i>Matrix Biology</i> , 2010 , 29, 194-201	11.4	94
10	Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. <i>Journal of Cardiac Failure</i> , 2010 , 16, 599-608	3.3	56
9	Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010 , 382, 293-301	3.4	36
8	Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. <i>Free Radical Biology and Medicine</i> , 2009 , 46, 1298-307	7.8	134
7	Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. <i>Archives of Toxicology</i> , 2009 , 83, 439-49	5.8	19
6	Low level and sub-chronic exposure to methylmercury induces hypertension in rats: nitric oxide depletion and oxidative damage as possible mechanisms. <i>Archives of Toxicology</i> , 2009 , 83, 653-62	5.8	56
5	Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress. <i>Thrombosis Research</i> , 2009 , 124, 349-55	8.2	26
4	Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. <i>European Journal of Pharmacology</i> , 2008 , 591, 224-30	5.3	41
3	Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. <i>European Journal of Pharmacology</i> , 2008 , 599, 110-6	5.3	27
2	Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. <i>Atherosclerosis</i> , 2008 , 198, 320-31	3.1	155
1	Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. <i>European Journal of Pharmacology</i> , 2004 , 498, 189-94	5.3	57